IM8 names Jay Shetty global ambassador, raises 2026 revenue outlook

Prenetics raised FY2026 IM8 revenue guidance to $190 million-$210 million from $180 million-$200 million after preliminary Q1 2026 IM8 revenue of $33.8 million, up nearly 6x year over year, and May 2026 revenue is tracking at about $15.5 million. The company also announced Jay Shetty as a global ambassador and shareholder, alongside additional partnership and leadership moves to support IM8 growth. PRE shares have returned over 100% over the past year, though the company remains unprofitable.

Analysis

PRE is transitioning from a “story stock” to a measurable consumer execution name, and that matters because the market is likely still underestimating how much of the valuation can be justified by growth durability rather than venture-style optionality. The combination of a higher revenue guide, high gross margin, and repeated affiliate/ambassador deals suggests management is buying distribution with equity rather than cash, which is capital-efficient now but can become a governance overhang if growth decelerates. The key read-through is that the market may start valuing IM8 less like a supplement launch and more like a branded consumer platform with recurring economics, which would support multiple expansion if quarterly revenue visibility stays above the current run-rate.

The second-order effect is on competitors in premium nutrition and influencer-led wellness: PRE is effectively showing that a globally distributed, founder-story + athlete + creator marketing stack can outpace traditional paid media economics. That raises the bar for smaller DTC wellness brands with weaker gross margins or less international reach, because PRE is proving scale can be achieved before profitability if CAC payback is short enough. The international mix is especially important: it reduces dependence on U.S. retail saturation and gives the brand more runway before domestic channel conflict becomes an issue.

The main risk is that the current growth rate is too steep to extrapolate cleanly beyond the next 2-3 quarters. If May’s pace normalizes or the ambassador-driven bump fades, the stock could de-rate quickly because a ~$246M equity value is already discounting a lot of future success; this is a classic setup where any miss is punished more than a beat is rewarded. Another tail risk is execution creep: as the company layers on partnerships, it may dilute economics if each new deal lifts awareness faster than contribution margin.

Contrarian view: consensus may be focusing too much on revenue acceleration and not enough on whether this is becoming a repeatable operating system or just a well-timed brand burst. If the company can sustain revenue per month near the latest run-rate for another two quarters, the market will likely re-rate PRE as a growth compounder; if not, the current momentum trade is vulnerable to a sharp multiple reset. The asymmetry is real, but it hinges on continued proof that demand is endogenous, not just celebrity-amplified.

Key Decisions for Investors

• Long PRE into the next quarterly print with a 6-10 week horizon; thesis is that the market keeps rewarding revenue acceleration and international scale, but trim aggressively if sequential monthly growth falls materially below the current implied run-rate.
• Use call spreads on PRE rather than outright equity for the next 1-2 quarters; upside is multiple expansion on sustained growth, while downside is a sharp de-rating if ambassador-driven demand proves temporary.
• Pair trade: long PRE / short a basket of weaker premium DTC consumer names over 1-3 months; PRE has better gross margin and more credible growth visibility, while many peers have inferior CAC efficiency and weaker international penetration.
• If PRE rallies >20% on the next update without a corresponding increase in forward guide, fade the move with a tactical short or hedge; at this market cap, the stock is more sensitive to guide quality than headline revenue beats.